Unfortunately, because the terms of law state that the settlement terms cannot be discussed, there isn’t much to report on this. However, the details we do know were released in an official press release rom Indivior yesterday. The statement was as follows:
Indivior PLC (LON: INDV) (“Indivior” or the “Company”) today announced that its U.S. subsidiary, Indivior Inc., together with Monosol Rx, LLC, entered into a settlement agreement with Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and Mylan N.V. (collectively, “Mylan”) resolving patent litigation related to SUBOXONE® (buprenorphine and naloxone) Sublingual Film. The litigation has been pending in the U.S. District Court for the District of Delaware and resulted from Mylan’s submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food & Drug Administration seeking approval to market generic versions of SUBOXONE® Film. The terms of the settlement are confidential.
As required by law, the parties will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
Shaun Thaxter, CEO of Indivior, said, “We are pleased to have amicably settled all outstanding litigation with Mylan. The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property. Further, as recently demonstrated with our newly granted ‘454 patent, we expect to expand the intellectual property estate for SUBOXONE® Film and vigorously assert and defend it.”